223 related articles for article (PubMed ID: 28835480)
1. Fabry disease: characterisation of the plasma proteome pre- and post-enzyme replacement therapy.
Heo SH; Kang E; Kim YM; Go H; Kim KY; Jung JY; Kang M; Kim GH; Kim JM; Choi IH; Choi JH; Jung SC; Desnick RJ; Yoo HW; Lee BH
J Med Genet; 2017 Nov; 54(11):771-780. PubMed ID: 28835480
[TBL] [Abstract][Full Text] [Related]
2. Differences in cleavage of globotriaosylceramide and its derivatives accumulated in organs of young Fabry mice following enzyme replacement therapy.
Kodama T; Tsukimura T; Kawashima I; Sato A; Sakuraba H; Togawa T
Mol Genet Metab; 2017; 120(1-2):116-120. PubMed ID: 27756537
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of enzyme-replacement-therapy with agalsidase alfa in 36 treatment-naïve Fabry disease patients.
Tsuboi K; Yamamoto H
BMC Pharmacol Toxicol; 2017 Jun; 18(1):43. PubMed ID: 28592315
[TBL] [Abstract][Full Text] [Related]
4. Complement activation and cellular inflammation in Fabry disease patients despite enzyme replacement therapy.
Laffer B; Lenders M; Ehlers-Jeske E; Heidenreich K; Brand E; Köhl J
Front Immunol; 2024; 15():1307558. PubMed ID: 38304433
[TBL] [Abstract][Full Text] [Related]
5. Reduced glucosylceramide in the mouse model of Fabry disease: correction by successful enzyme replacement therapy.
Quinta R; Rodrigues D; Assunção M; Macedo MF; Azevedo O; Cunha D; Oliveira P; Sá Miranda MC
Gene; 2014 Feb; 536(1):97-104. PubMed ID: 24334116
[TBL] [Abstract][Full Text] [Related]
6. Plasma globotriaosylsphingosine as a biomarker of Fabry disease.
Togawa T; Kodama T; Suzuki T; Sugawara K; Tsukimura T; Ohashi T; Ishige N; Suzuki K; Kitagawa T; Sakuraba H
Mol Genet Metab; 2010 Jul; 100(3):257-61. PubMed ID: 20409739
[TBL] [Abstract][Full Text] [Related]
7. Is globotriaosylceramide a useful biomarker in Fabry disease?
Young E; Mills K; Morris P; Vellodi A; Lee P; Waldek S; Winchester B
Acta Paediatr Suppl; 2005 Mar; 94(447):51-4; discussion 37-8. PubMed ID: 15895713
[TBL] [Abstract][Full Text] [Related]
8. Reduction of elevated plasma globotriaosylsphingosine in patients with classic Fabry disease following enzyme replacement therapy.
van Breemen MJ; Rombach SM; Dekker N; Poorthuis BJ; Linthorst GE; Zwinderman AH; Breunig F; Wanner C; Aerts JM; Hollak CE
Biochim Biophys Acta; 2011 Jan; 1812(1):70-6. PubMed ID: 20851180
[TBL] [Abstract][Full Text] [Related]
9. Enzyme replacement therapy in two Japanese siblings with Fabry disease, and its effectiveness on angiokeratoma and neuropathic pain.
Furujo M; Kubo T; Kobayashi M; Ohashi T
Mol Genet Metab; 2013 Nov; 110(3):405-10. PubMed ID: 23906479
[TBL] [Abstract][Full Text] [Related]
10. Plasma lyso-Gb3: a biomarker for monitoring fabry patients during enzyme replacement therapy.
Sakuraba H; Togawa T; Tsukimura T; Kato H
Clin Exp Nephrol; 2018 Aug; 22(4):843-849. PubMed ID: 29288396
[TBL] [Abstract][Full Text] [Related]
11. Diurnal Variation of Urinary Fabry Disease Biomarkers during Enzyme Replacement Therapy Cycles.
Boutin M; Lavoie P; Menkovic I; Toupin A; Abaoui M; Elidrissi-Elawad M; Arthus MF; Fortier C; Ménard C; Maranda B; Bichet DG; Auray-Blais C
Int J Mol Sci; 2020 Aug; 21(17):. PubMed ID: 32854306
[TBL] [Abstract][Full Text] [Related]
12. Substrate reduction augments the efficacy of enzyme therapy in a mouse model of Fabry disease.
Marshall J; Ashe KM; Bangari D; McEachern K; Chuang WL; Pacheco J; Copeland DP; Desnick RJ; Shayman JA; Scheule RK; Cheng SH
PLoS One; 2010 Nov; 5(11):e15033. PubMed ID: 21124789
[TBL] [Abstract][Full Text] [Related]
13. Globotriaosylceramide is correlated with oxidative stress and inflammation in Fabry patients treated with enzyme replacement therapy.
Biancini GB; Vanzin CS; Rodrigues DB; Deon M; Ribas GS; Barschak AG; Manfredini V; Netto CB; Jardim LB; Giugliani R; Vargas CR
Biochim Biophys Acta; 2012 Feb; 1822(2):226-32. PubMed ID: 22085605
[TBL] [Abstract][Full Text] [Related]
14. Separation and Analysis of Lactosylceramide, Galabiosylceramide, and Globotriaosylceramide by LC-MS/MS in Urine of Fabry Disease Patients.
Boutin M; Menkovic I; Martineau T; Vaillancourt-Lavigueur V; Toupin A; Auray-Blais C
Anal Chem; 2017 Dec; 89(24):13382-13390. PubMed ID: 29099167
[TBL] [Abstract][Full Text] [Related]
15. One Year of Enzyme Replacement Therapy Reduces Globotriaosylceramide Inclusions in Podocytes in Male Adult Patients with Fabry Disease.
Najafian B; Tøndel C; Svarstad E; Sokolovkiy A; Smith K; Mauer M
PLoS One; 2016; 11(4):e0152812. PubMed ID: 27081853
[TBL] [Abstract][Full Text] [Related]
16. Enzyme replacement therapy partially prevents invariant Natural Killer T cell deficiency in the Fabry disease mouse model.
Macedo MF; Quinta R; Pereira CS; Sa Miranda MC
Mol Genet Metab; 2012 May; 106(1):83-91. PubMed ID: 22425450
[TBL] [Abstract][Full Text] [Related]
17. Treatment of neutral glycosphingolipid lysosomal storage diseases via inhibition of the ABC drug transporter, MDR1. Cyclosporin A can lower serum and liver globotriaosyl ceramide levels in the Fabry mouse model.
Mattocks M; Bagovich M; De Rosa M; Bond S; Binnington B; Rasaiah VI; Medin J; Lingwood C
FEBS J; 2006 May; 273(9):2064-75. PubMed ID: 16724420
[TBL] [Abstract][Full Text] [Related]
18. Characterization of Fabry mice treated with recombinant adeno-associated virus 2/8-mediated gene transfer.
Choi JO; Lee MH; Park HY; Jung SC
J Biomed Sci; 2010 Apr; 17(1):26. PubMed ID: 20398385
[TBL] [Abstract][Full Text] [Related]
19. Enzyme Replacement Therapy Clears Gb3 Deposits from a Podocyte Cell Culture Model of Fabry Disease but Fails to Restore Altered Cellular Signaling.
Braun F; Blomberg L; Brodesser S; Liebau MC; Schermer B; Benzing T; Kurschat CE
Cell Physiol Biochem; 2019; 52(5):1139-1150. PubMed ID: 30990584
[TBL] [Abstract][Full Text] [Related]
20. Biomolecules damage and redox status abnormalities in Fabry patients before and during enzyme replacement therapy.
Biancini GB; Jacques CE; Hammerschmidt T; de Souza HM; Donida B; Deon M; Vairo FP; Lourenço CM; Giugliani R; Vargas CR
Clin Chim Acta; 2016 Oct; 461():41-6. PubMed ID: 27458128
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
